What Does Sermonix Pharmaceuticals Do?

Total employees35
HeadquartersColumbus
Founded2013

Sermonix Pharmaceuticals Inc. is a privately held biopharmaceutical company specializing in the development and commercialization of novel therapeutics for women's health, with a primary emphasis on treating endocrine-resistant metastatic breast cancer. Their lead investigational drug, lasofoxifene, is an oral, selective estrogen receptor modulator (SERM) being evaluated for its potential in treating ESR1-mutated metastatic breast cancer. Sermonix is dedicated to addressing significant unmet medical needs in women's oncology by advancing targeted therapies aimed at improving patient outcomes and quality of life.

Where Is Sermonix Pharmaceuticals's Headquarters?

Sermonix Pharmaceuticals officeSermonix Pharmaceuticals officeSermonix Pharmaceuticals officeSermonix Pharmaceuticals office
*Images sourced via web search. Rights belong to original owners

HQ Function

Serves as the central hub for strategic decision-making, clinical development oversight, research initiatives, corporate administration, and business development activities.

Notable Features:

Located in a modern office building within the Arena District, known for its vibrant business environment and accessibility.

Work Culture:

A dynamic, science-driven, and patient-focused work environment. The culture likely emphasizes collaboration, innovation, and a strong commitment to advancing women's health.

HQ Significance:

The Columbus, Ohio location provides access to a growing life sciences ecosystem, research institutions, and a skilled talent pool, supporting the company's research and development efforts.

Values Reflected in HQ: The choice of a modern, professional office space in a key business district likely reflects Sermonix's commitment to innovation, growth, and establishing a strong presence in the biopharmaceutical industry.

Location:

Sermonix Pharmaceuticals' global presence is primarily driven by its clinical trial operations and strategic partnerships. While headquartered in the U.S., the company conducts multinational clinical studies for lasofoxifene, involving research sites and investigators across North America, Europe, and potentially other regions. Their business development efforts also span globally as they seek collaborations and explore market access for their therapies.

Street Address:

394 W. Nationwide Blvd., Suite 200

City:

Columbus

State/Province:

Ohio

Country:

USA

Where Else Does Sermonix Pharmaceuticals Operate Around the World?

Not Publicly Listed

Address: Not Publicly Listed

If such presences exist, they would likely support geographically dispersed clinical trials, regulatory affairs, or business development in key markets.

Buying Intent Signals for Sermonix Pharmaceuticals

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Sermonix Pharmaceuticals? Meet the Executive Team

As of April 2025, Sermonix Pharmaceuticals' leadership includes:

David Portman, M.D. - Founder, President & Chief Executive Officer
Anthony H. Wild, Ph.D. - Chairman of the Board
Miriam L. Portman, M.A. - Co-Founder & Chief Operating Officer
James C.A. Symons, BVSc, MS, PhD, DACVP - Chief Medical Officer
Paul Plourde, M.D. - Vice President, Clinical Development
Elizabeth Attias, M.Sc., M.B.A. - Vice President, Business Development & Strategy
Barry Komm, Ph.D. - Chief Scientific Officer

Who's Investing in Sermonix Pharmaceuticals?

Sermonix Pharmaceuticals has been backed by several prominent investors over the years, including:

Pierre Fabre Invest
The AMR Action Fund
Other undisclosed private investors and venture capital entities

What Leadership Changes Has Sermonix Pharmaceuticals Seen Recently?

Hire1
Exits0

Based on publicly available information in the last 12-18 months, Sermonix has maintained a stable core executive team with some strategic additions. For instance, Dr. Barry Komm was appointed CSO in late 2022, strengthening their scientific leadership.

Departures

N/A, No major executive departures publicly reported in the last 12 months.

New Appointments:

Barry Komm, Ph.D., Dr. Barry Komm appointed as Chief Scientific Officer to lead scientific strategy and research efforts.

What Technology (Tech Stack) Is Used bySermonix Pharmaceuticals?

Discover the tools Sermonix Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Sermonix Pharmaceuticals Email Formats and Examples

Sermonix Pharmaceuticals most commonly uses the email format of the employee's first initial followed by their last name. Other formats might be used less frequently.

flast@sermonix.com

Format

jdoe@sermonix.com

Example

80%

Success rate

What's the Latest News About Sermonix Pharmaceuticals?

GlobeNewswire • December 13, 2023

Sermonix Pharmaceuticals Announces Strategic Investment to Advance Lasofoxifene for ER+/HER2- Metastatic Breast Cancer with an ESR1 Mutation

Sermonix Pharmaceuticals Inc. announced a strategic investment from the AMR Action Fund and an existing investor. The proceeds will be used to advance the clinical development of lasofoxifene, its lead investigational drug for ER+/HER2- metastatic breast cancer with an ESR1 mutation....more

Sermonix Pharmaceuticals (Press Release) • October 21, 2023

Sermonix Pharmaceuticals Presents Updated Results from its Phase 2 ELAINE-1 and ELAINE-2 Studies of Lasofoxifene at ESMO Congress 2023

Sermonix presented updated, encouraging results from its ELAINE-1 and ELAINE-2 Phase 2 studies evaluating lasofoxifene in ER+/HER2- metastatic breast cancer patients with ESR1 mutations at the European Society for Medical Oncology (ESMO) Congress 2023....more

GlobeNewswire • September 27, 2023

Sermonix Pharmaceuticals Announces Positive Results from Post-Hoc Analysis of ELAINE-2 Trial Evaluating Lasofoxifene plus Abemaciclib in ER+/HER2- Metastatic Breast Cancer Patients with ESR1 Mutations

Sermonix announced positive findings from a post-hoc analysis of the ELAINE-2 trial, showing lasofoxifene combined with abemaciclib demonstrated notable clinical benefit in heavily pre-treated ER+/HER2- metastatic breast cancer patients with ESR1 mutations....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Sermonix Pharmaceuticals, are just a search away.